Novartis AG
- Jurisdiction
Switzerland - LEI
5493007HIVTX6SY6XD66 - ISIN
CH0012005267 (NOVN.SW )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€136.10 21.5% undervalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Read full profile
Fundamentals
- Net revenue
€47.07B - Gross margin
76.2% - EBIT
€14.23B - EBIT margin
30.2% - Net income
€11.65B - Net margin
24.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
CHF 3.50 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
57.3%
Analyst ratings
7 analysts rated this company in the past 90 days. The average target price is €107.18, this is a change of -4.3% compared to the current price.
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| N/A | N/A |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| John D. Spears |
|
|
|
Sell |